Lumea has been recognized with a 2025 Global Recognition Award for its remarkable contributions to healthcare technology, especially in advancing global cancer diagnostics. The company’s story began in 2013 when two pathologists, Drs. Jared Szymanski and Matthew O. Leavitt identified persistent shortcomings in digital pathology and set out to address them, aiming to reshape diagnostic practices on a global scale. Their vision attracted mechanical engineer Mark Evans and software engineer Andy Ivie, whose expertise in 2014 enabled the development of a comprehensive digital software platform, while the acquisition of a Romanian histotechnology company in 2015 provided the foundation for Lumea’s distinctive collection of patented pre-analytical tissue-handling technologies.

Innovation that Sets New Standards

Lumea’s strategy for innovation is rooted in a nuanced understanding of the practical difficulties pathologists encounter, as traditional methods have long relied on microscopes, glass slides, and hazardous specimen transport. The company designed a collection of patented pre-analytical technologies that guarantee optimal specimen care from the outset, addressing inefficiencies and risks in conventional pathology workflows. The BxBoard® system is a prime example, as it replaces outdated specimen transport bottles, reduces biohazard waste in histology labs by 136%, lowers plastic waste by 83%, and curtails formalin use—a significant health and environmental concern—by 89%.

The BxChip® further exemplifies Lumea’s commitment to progress, as it improves tissue representation on glass slides and increases tissue surface area by 14.5% and biopsy core length by 31.8%. This advancement has resulted in a 9.3% increase in accurate cancer detection rates, which has substantial implications for patient outcomes worldwide. Laboratories that have adopted the BxChip® report notable time savings, which is critical in an environment characterized by declining reimbursement rates and significant staffing shortages. At the same time, Lumea’s platform extends to advanced digital pathology viewers and integrated AI tools, supporting remote diagnostics and enhanced workflow efficiencies.

Disruption Through User-Driven Design and Global Reach

Lumea’s approach, shaped by pathologists’ experiences, distinguishes it from companies founded by software engineers, as every innovation is crafted to meet the practical needs of its users. Collaboration with pathologists and laboratory professionals ensures that solutions remain relevant and valuable. This allows Lumea to challenge established practices and make advanced diagnostic capabilities accessible to various pathology groups. The company’s early focus on prostate cancer, a significant global health issue, has since broadened to encompass a range of cancer types, reflecting a sustained drive to address emerging healthcare challenges.

Lumea’s extensive patent portfolio and its achievements in originality, technological advancement, and shifting established practices have set new benchmarks for digital pathology. At the same time, the upcoming introduction of pre-analytical technology for breast biopsies will further expand its influence. Over 2 million specimen diagnoses have benefited from Lumea’s technology, and widespread positive feedback from users highlights the substantial value of its solutions. Hundreds of laboratories and pathologists worldwide have adopted Lumea’s technology, demonstrating the company’s ability to deliver meaningful change across the sector.

Final Words

Lumea’s recognition with a 2025 Global Recognition Award affirms its exceptional leadership, relentless pursuit of innovation, and dedication to improving global cancer diagnostics. The company’s advanced technologies have improved digital pathology while providing tangible benefits for patients, healthcare providers, and the environment, establishing new standards for the industry.

Visionary leadership, technical expertise, and a strong sense of social responsibility have driven significant progress on a global scale, as demonstrated by Lumea’s journey. The mission to reduce misdiagnosis and improve patient care worldwide inspires the fight against cancer and sets a higher standard for excellence in healthcare technology.